652,750 Shares in Zentalis Pharmaceuticals, Inc. $ZNTL Acquired by ADAR1 Capital Management LLC

Key Points

• ADAR1 Capital Management acquired 652,750 shares of Zentalis Pharmaceuticals in the second quarter, valued at approximately $3.17 million and representing about 0.91% of the company.
• Zentalis reported a quarterly loss of $0.59 per share, missing analyst expectations of a $0.49 loss. Analysts expect a full-year loss of approximately $2.14 per share.
• The stock opened at $3.88, while analysts maintain an average “Hold” rating and a $6.75 price target; insider ownership also increased after major shareholder Group Walters bought 4.34 million shares.

ADAR1 Capital Management LLC acquired a new stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 652,750 shares of the company's stock, valued at approximately $3,166,000. ADAR1 Capital Management LLC owned approximately 0.91% of Zentalis Pharmaceuticals as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in ZNTL. CTC Alternative Strategies Ltd. bought a new position in Zentalis Pharmaceuticals during the 1st quarter valued at about $29,000. The Manufacturers Life Insurance Company bought a new stake in shares of Zentalis Pharmaceuticals in the second quarter worth approximately $69,000. State of Wyoming bought a new stake in shares of Zentalis Pharmaceuticals in the second quarter worth approximately $91,000. Sivia Capital Partners LLC purchased a new position in shares of Zentalis Pharmaceuticals during the fourth quarter valued at approximately $27,000. Finally, Voleon Capital Management LP bought a new position in Zentalis Pharmaceuticals during the third quarter valued at approximately $41,000.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock opened at $3.88 on Wednesday. Zentalis Pharmaceuticals, Inc. has a 1 year low of $1.21 and a 1 year high of $6.95. The firm's 50 day moving average price is $4.36 and its 200-day moving average price is $3.70. The stock has a market cap of $278.08 million, a P/E ratio of -1.99 and a beta of 1.92.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.10). As a group, equities analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.14 EPS for the current year.

Insider Activity at Zentalis Pharmaceuticals

In related news, major shareholder Group Walters bought 4,335,000 shares of the company's stock in a transaction dated Friday, August 14th. The stock was purchased at an average price of $3.50 per share, for a total transaction of $15,172,500.00. Following the acquisition, the insider owned 17,844,973 shares in the company, valued at $62,457,405.50. This trade represents a 32.09% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 3.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Mizuho started coverage on Zentalis Pharmaceuticals in a research note on Friday, July 17th. They set an "outperform" rating and a $8.00 price target for the company. Rodman & Renshaw started coverage on shares of Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They set a "buy" rating and a $11.00 price target for the company. Wall Street Zen cut shares of Zentalis Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Zentalis Pharmaceuticals in a report on Monday, July 6th. Four investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $6.75.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis' research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company's lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.

Want to see what other hedge funds are holding ZNTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source